Prothena collaborates with scientists with expertise in our areas of interest to test and characterize our therapeutic antibody candidates. We also engage with leading clinical experts in our therapeutic areas for feedback and guidance on our programs.
We may pursue many paths in the development of new medicines; including developing therapies independently, under a license agreement, or in collaboration with other companies. Prothena also seeks strategic alliances that leverage our insights in amyloid or cell adhesion to generate innovative potential antibody therapeutics.
Our worldwide collaboration with Roche to develop and commercialize PRX002 for the potential treatment of Parkinson’s disease and other related synucleinopathies is an example of this strategy.
For more information on partnering or collaborating with Prothena, contact us at firstname.lastname@example.org.